Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atorvastatin after surgery in oral squamous cell carcinoma
IRCT20230627058596N1Phase 3Completed
- Sponsor
- Alborz University of Medical Sciences
- Start
- Aug 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial of atorvastatin in Oral Mucosal Carcinoma (2 arms), sponsored by Alborz University of Medical Sciences. Primary endpoints: Superoxide dismutase in saliva, Beta-2 microglobulin in saliva and 3 more. Started Aug 2023; status: completed.
02
Drugs
atorvastatin
03
Conditions
Oral Mucosal Carcinoma
Beyond the preview
Go deeper on IRCT20230627058596N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20230627058596N1.